Popular Trials
Intervention arm for Pectoralis Minor Length Syndrome
Recruiting1 award1 criteria
Hayden, Idaho
The goal of this clinical trial is to test normal participants. The main question it aims to answer is: • Do the participant's pectoralis minor muscles change length immediately after performing an exercise that recruits the scapular retractor muscles? Participants will have their pectoralis minor muscle measured, then perform an exercise recruiting the scapular retractor muscles, and then have their pectoralis muscle measured again.
Behavioural Intervention
Mirtazapine for Methamphetamine and Opioid Use Disorders
Recruiting0 awardsPhase 2
Spokane, Washington
"This trial will test whether Mirtazapine (MZP), a medication known for treating certain conditions, can help reduce methamphetamine use and related harmful behaviors in patients receiving treatment for opioid use disorder
Anti-tumor antibiotic
Venetoclax + HMA for Acute Myeloid Leukemia
Recruiting1 awardPhase 2
Post Falls, Idaho
This trial is comparing two different treatments for older and unfit patients with acute myeloid leukemia and FLT3 mutations. One treatment includes the drugs azacitidine and venetoclax, while the
Procedure
Ivabradine and IVIG for Long COVID Syndrome
Recruiting0 awardsPhase 2
Spokane, Washington
This trial is a flexible study that can be used in different healthcare and community settings to help treat autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (
Popular Filters
Trials With No Placebo
Behavioral Intervention
Contingency Management for Alcoholism
Recruiting1 award1 criteria
Spokane, Washington
This trial is testing a program called Contingency Management to see if it can help adults who want to drink less alcohol. It is a study where participants are randomly assigned to different groups to see if
Behavioural Intervention
Telehealth Lifestyle and Exercise for COPD and OSA
Recruiting1 award5 criteria
Spokane, Washington
This trial will test a telehealth program for 400 overweight and obese patients with COPD and OSA. Participants will be split into two groups, one receiving the telehealth intervention and the other receiving
Dnase - Discontinue for Cystic Fibrosis
Recruiting1 award6 criteria
Spokane, Washington
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be safely stopped. This SIMPLIFY sub-study is being done to test whether or not it is safe to stop taking dornase alfa (Dnase) in those people that are also taking elexacaftor/tezacaftor/ivacaftor (ETI). ETI is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del mutation. The three drugs that make up ETI work together to allow many more chloride ions to move into and out of the cells, improving the balance of salt and water in the lungs. These changes result in better clearance of mucus from the lungs and improvements in lung function. Dornase alfa (Dnase) also improves clearance of mucus from the lungs to support lung function and has been available to people with CF for many years. Dnase is considered to be relatively burdensome and it is not known whether Dnase can improve or maintain lung function above what is already gained through ETI use. The goal of this SIMPLIFY sub-study is to get information about whether or not it is safe to stop Dnase by testing if there is a change in lung function in participants with cystic fibrosis (CF) who are assigned to stop taking Dnase as compared to those who are assigned to keep taking Dnase while continuing to take ETI. This is a sub study of master protocol SIMPLIFY-IP-19, NCT04378153. The sub study investigating the impact of discontinuing and continuing hypertonic saline is registered under NCTXXXXXXX (will add once available).
HS-Discontinue for Cystic Fibrosis
Recruiting1 award6 criteria
Spokane, Washington
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be safely stopped. This SIMPLIFY sub-study is being done to test whether or not it is safe to stop taking inhaled hypertonic saline in those people that are also taking elexacaftor/tezacaftor/ivacaftor (ETI). ETI is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del mutation. The three drugs that make up ETI work together to allow many more chloride ions to move into and out of the cells, improving the balance of salt and water in the lungs. These changes result in better clearance of mucus from the lungs and improvements in lung function. Inhaled hypertonic saline (HS) also improves clearance of mucus from the lungs to support lung function and has been available to people with CF for many years. HS is considered to be relatively burdensome and it is not known whether HS can improve or maintain lung function above what is already gained through ETI use. The goal of this SIMPLIFY sub-study is to get information about whether or not it is safe to stop hypertonic saline by testing if there is a change in lung function in participants with cystic fibrosis (CF) who are assigned to stop taking HS as compared to those who are assigned to keep taking HS while continuing to take ETI. This is a sub study of master protocol SIMPLIFY-IP-19, NCT04378153. The sub study investigating the impact of discontinuing and continuing dornase alfa is registered under NCTXXXXXXX (will add once available).
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.